Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

We summarised data from 38 eligible studies, which presented risk estimates for at least one endpoint, including two RCT and 27 cohort-studies: 205565 patients with information on 25OHD status and 2022 taking vitamin D supplementation with a total of 1197 admitted to the ICU or who needed invasive mechanical ventilation or intubation and hospital stay, and more than 910 Covid-19 deaths.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis

Source: Article title.

Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis

Systematic review · PLoS ONE · 2022

Original publication title

Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis

Oriana D’Ecclesiis; Costanza Gavioli; Chiara Martinoli; Sara Raimondi; Susanna Chiocca; Claudia Miccolo; Paolo Bossi; Diego Cortinovis; Ferdinando Chiaradonna; Roberta Palorini; Federica Faciotti; Federica Bellerba; Stefania Canova; Costantino Jemos; Emanuela Omodeo Salé; Aurora Gaeta; Barbara Zerbato; Patrizia Gnagnarella; Sara Gandini

© 2022 D’Ecclesiis et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

To assess the evidence on SARS-CoV2 infection and Covid-19 in relation to deficiency and supplementation of vitamin D, we conducted a systematic review up to April 2021. We summarised data from 38 eligible studies, which presented risk estimates for at least one endpoint, including two RCT and 27 cohort-studies: 205565 patients with information on 25OHD status and 2022 taking vitamin D supplementation with a total of 1197 admitted to the ICU or who needed invasive mechanical ventilation or intubation and hospital stay, and more than 910 Covid-19 deaths.

Primary outcomes were severity and mortality and the main aim was to evaluate the association with vitamin D supplementation. Random effects models showed that supplementation was associated with a significant lower risk of both Covid-19 severe disease (SRR 0.38, 95% CI 0.20 to 0.72, 6 studies) and mortality (SRR 0.35, 95% CI 0.17 to 0.70, 8 studies). There were no statistically significant dose differences between studies: summary estimates with regular doses remain statistically significant, suggesting that higher doses are not necessary. For patients on vitamin D supplementation, a greater reduction in mortality risk emerged in older individuals and at higher latitudes.

Regarding the quality of studies, assessed using the New Castle-Ottawa quality scale, the analysis revealed in most cases no statistically significant differences between low, medium or high quality studies. We found significant associations of vitamin D supplementation with Covid-19, encompassing risks of disease worsening and mortality, especially in seasons characterized by 25OHD deficiency and with not severe patients. Dedicated randomized clinical studies are encouraged to confirm these results.

Authors’ abstract

To assess the evidence on SARS-CoV2 infection and Covid-19 in relation to deficiency and supplementation of vitamin D, we conducted a systematic review up to April 2021. We summarised data from 38 eligible studies, which presented risk estimates for at least one endpoint, including two RCT and 27 cohort-studies: 205565 patients with information on 25OHD status and 2022 taking vitamin D supplementation with a total of 1197 admitted to the ICU or who needed invasive mechanical ventilation or intubation and hospital stay, and more than 910 Covid-19 deaths.

Primary outcomes were severity and mortality and the main aim was to evaluate the association with vitamin D supplementation. Random effects models showed that supplementation was associated with a significant lower risk of both Covid-19 severe disease (SRR 0.38, 95% CI 0.20 to 0.72, 6 studies) and mortality (SRR 0.35, 95% CI 0.17 to 0.70, 8 studies). There were no statistically significant dose differences between studies: summary estimates with regular doses remain statistically significant, suggesting that higher doses are not necessary. For patients on vitamin D supplementation, a greater reduction in mortality risk emerged in older individuals and at higher latitudes.

Regarding the quality of studies, assessed using the New Castle-Ottawa quality scale, the analysis revealed in most cases no statistically significant differences between low, medium or high quality studies. We found significant associations of vitamin D supplementation with Covid-19, encompassing risks of disease worsening and mortality, especially in seasons characterized by 25OHD deficiency and with not severe patients. Dedicated randomized clinical studies are encouraged to confirm these results.

Publication and source details

Original title: Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis

Oriana D’Ecclesiis; Costanza Gavioli; Chiara Martinoli; Sara Raimondi; Susanna Chiocca; Claudia Miccolo; Paolo Bossi; Diego Cortinovis; Ferdinando Chiaradonna; Roberta Palorini; Federica Faciotti; Federica Bellerba; Stefania Canova; Costantino Jemos; Emanuela Omodeo Salé; Aurora Gaeta; Barbara Zerbato; Patrizia Gnagnarella; Sara Gandini

PLoS ONE · 2022

Competing Interests: The authors have declared that no competing interests exist.

‡ OD and CG are co-first authors on this work.

* E-mail: patrizia.gnagnarella@ieo.it (PG); sara.gandini@ieo.it (SG)
© 2022 D’Ecclesiis et al2022D’Ecclesiis et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Grant Regione Lombardia DECRETO N. 7082 Del 17/06/2020. Identificativo Atto n. 366 https://orcid.org/0000-0002-1348-4548 Gandini Sara The European Institute of Oncology Grant Regione Lombardia. (DECRETO N. 7082 Del 17/06/2020. Identificativo Atto n. 366: COVitaminD Trial: prevenzione di complicanze da COVID-19 in pazienti oncologici). The European Institute of Oncology, Milan, Italy is partially supported by the Italian Ministry of Health with Ricerca Corrente and 5×1,000 funds.Federica Bellerba is a Ph.D. student within the European School of Molecular Medicine (SEMM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T02:43:17.344384+00:00

DOI: 10.1371/journal.pone.0268396 · PMC9258852